Gilead Taps Weber Shandwick, Plus Other Pharma News
Charting the future of public relations
Holmes Report
CEO

Gilead Taps Weber Shandwick, Plus Other Pharma News

Gilead Sciences has appointed Weber Shandwick to provide public relations support for the drug Hepsera for the treatment of chronic hepatitis B in the United States, and launch it in Europe.

Paul Holmes

NEW YORK—Gilead Sciences, a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases, has appointed Weber Shandwick to provide public relations support for the drug Hepsera for the treatment of chronic hepatitis B in the United States, and launch it in Europe.

“Weber Shandwick’s creative approach, expertise in scientific communications and previous experience in hepatitis B and C were the deciding factors in this important business decision,” said Amy Flood, associate director, public affairs for Gilead Sciences.

Hepatitis B attacks the liver and can cause chronic infection, leading to cirrhosis of the liver, liver cancer and death in up to a third of patients.

According to Laura Schoen, president of Weber Shandwick’s global healthcare practice. “A key goal of our public relations efforts will be to drive more patients to physicians for early diagnosis and treatment.”

NEW YORK—Porter Novelli has been appointed agency of record by Shire U.S. and will handle public relations and marketing communications for Adderall XR, a treatment of attention deficit and hyperactivity disorder (ADHD).
Shire Pharmaceuticals Group has a strategic focus in four therapeutic areas: central nervous system disorders (CNS), oncology, gastrointestinal (GI) and anti-infectives.

NEW YORK—GlaxoSmithKline has selected GCI Group to support global communications for Imigran (sumatriptan), the company’s flagship migraine product. GCI’s New York, Chicago, London and Toronto offices will work on the account.

View Style:

Load 3 More
comments powered by Disqus